European Commission approves Enhertu + pertuzumab for the 1st-line treatment of patients with HER2-positive metastatic breast cancer – AstraZeneca + Daiichi Sankyo
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the 1st-line treatment of adult patients with unresectable… read more.
